GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (NAS:CDXS) » Definitions » Asset Turnover

Codexis (Codexis) Asset Turnover : 0.12 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Codexis Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Codexis's Revenue for the three months ended in Mar. 2024 was $17.07 Mil. Codexis's Total Assets for the quarter that ended in Mar. 2024 was $143.06 Mil. Therefore, Codexis's Asset Turnover for the quarter that ended in Mar. 2024 was 0.12.

Asset Turnover is linked to ROE % through Du Pont Formula. Codexis's annualized ROE % for the quarter that ended in Mar. 2024 was -55.49%. It is also linked to ROA % through Du Pont Formula. Codexis's annualized ROA % for the quarter that ended in Mar. 2024 was -32.17%.


Codexis Asset Turnover Historical Data

The historical data trend for Codexis's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codexis Asset Turnover Chart

Codexis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 0.37 0.45 0.56 0.36

Codexis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.10 0.05 0.18 0.12

Competitive Comparison of Codexis's Asset Turnover

For the Biotechnology subindustry, Codexis's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Codexis's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Codexis's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Codexis's Asset Turnover falls into.



Codexis Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Codexis's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=70.143/( (250.393+136.561)/ 2 )
=70.143/193.477
=0.36

Codexis's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=17.073/( (136.561+149.559)/ 2 )
=17.073/143.06
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Codexis  (NAS:CDXS) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Codexis's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-46.02/82.941
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-46.02 / 68.292)*(68.292 / 143.06)*(143.06/ 82.941)
=Net Margin %*Asset Turnover*Equity Multiplier
=-67.39 %*0.4774*1.7248
=ROA %*Equity Multiplier
=-32.17 %*1.7248
=-55.49 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Codexis's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-46.02/143.06
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-46.02 / 68.292)*(68.292 / 143.06)
=Net Margin %*Asset Turnover
=-67.39 %*0.4774
=-32.17 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Codexis Asset Turnover Related Terms

Thank you for viewing the detailed overview of Codexis's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Codexis (Codexis) Business Description

Traded in Other Exchanges
Address
200 Penobscot Drive, Redwood, CA, USA, 94063
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases, etc. The company operates in two business segments namely Performance Enzymes and Novel Biotherapeutics. It generates maximum revenue from the Performance Enzymes segment. Geographically, it derives a majority of revenue from the APAC.
Executives
Byron L Dorgan director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Kevin Norrett officer: Chief Operating Officer C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Margaret Nell Fitzgerald officer: See Remarks ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Sriram Ryali officer: Chief Financial Officer C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306
Stephen George Dilly director, officer: See Remarks C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
John J Nicols director, officer: President and CEO ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801
H Stewart Parker director
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Dennis P Wolf director 1101 EAST MEADOW DR, PALO ALTO CA 94303
Patrick Y Yang director C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990
Bernard J Kelley director
Esther Martinborough director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Jennifer Aaker director C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Alison Moore director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Thomas R Baruch director 1 LETTERMAN DRIVE, BUILDING C, SUITE CM500, SAN FRANCISCO CA 94129